Evaluation of Candidates for Upfront Docetaxel Therapy Among Patients With Metastatic Castration-sensitive Prostate Cancer from a Retrospective Multicenter Study (MAHOROBA study)
Patients with mCSPC who have high lactate dehydrogenase levels and a Gleason grade 5 may be candidates for upfront docetaxel therapy, as they may otherwise miss the chance to receive adequate doses for prostate cancer.
Authors
- Akihide Hirayama (ORCID: https://orcid.org/0000-0002-2261-5925)
- Nobuo Oyama
- Kiyohide Fujimoto (ORCID: https://orcid.org/0000-0003-1507-2464)
- Tomonori Nakahama
- Ken Fujimoto (ORCID: https://orcid.org/0000-0001-5222-3327)
- Kenta Onishi (ORCID: https://orcid.org/0000-0001-5716-5904)
- Atsushi Tomioka (ORCID: https://orcid.org/0000-0001-7008-1502)
- Nobumichi Tanaka (ORCID: https://orcid.org/0000-0001-9242-7877)
- Yoriaki Kagebayashi
- Takeshi Otani
- Yasushi Nakai (ORCID: https://orcid.org/0000-0002-3255-4839)
- Masahiro Tanaka (ORCID: https://orcid.org/0000-0002-7067-0208)
- Yoshihiro Matsumoto (ORCID: https://orcid.org/0000-0003-2756-5290)
- Kenji Otsuka
Institutions
- Osaka Kaisei Hospital (JP)
- Hoshigaoka Medical Center (JP)
- Nara City Hospital (JP)
- Shioda General Hospital (JP)
- Jikei University Kashiwa hospital (JP)
- Nara Prefecture General Medical Center (JP)
- Nara Medical University (JP)
- Kindai University (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-03-28
- DOI
- https://doi.org/10.21873/anticanres.17546
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00